Equities Analysts Issue Forecasts for ResMed Q1 Earnings

ResMed Inc. (NYSE:RMD) – Zacks Research boosted their Q1 2026 earnings per share estimates for ResMed in a report issued on Thursday, May 22nd. Zacks Research analyst R. Department now forecasts that the medical equipment provider will post earnings of $2.37 per share for the quarter, up from their prior forecast of $2.36. The consensus estimate for ResMed’s current full-year earnings is $9.47 per share. Zacks Research also issued estimates for ResMed’s Q2 2026 earnings at $2.48 EPS, Q3 2026 earnings at $2.51 EPS, FY2026 earnings at $9.83 EPS and FY2027 earnings at $10.71 EPS.

A number of other analysts also recently commented on the company. Needham & Company LLC reiterated a “hold” rating on shares of ResMed in a research report on Friday, January 31st. Morgan Stanley set a $286.00 target price on ResMed and gave the stock an “overweight” rating in a research report on Tuesday, May 20th. KeyCorp set a $274.00 target price on ResMed in a research report on Thursday, April 24th. Wall Street Zen downgraded ResMed from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, Piper Sandler decreased their target price on ResMed from $260.00 to $248.00 and set a “neutral” rating on the stock in a research report on Thursday, April 24th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $259.33.

ResMed Stock Down 1.0%

RMD opened at $243.03 on Monday. The business’s fifty day moving average is $227.88 and its two-hundred day moving average is $234.16. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.29 and a current ratio of 3.33. The company has a market cap of $35.63 billion, a price-to-earnings ratio of 28.69, a PEG ratio of 1.53 and a beta of 0.78. ResMed has a one year low of $179.42 and a one year high of $263.05.

ResMed (NYSE:RMD) last posted its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $2.37 earnings per share for the quarter, beating analysts’ consensus estimates of $2.36 by $0.01. The firm had revenue of $1.29 billion for the quarter, compared to the consensus estimate of $1.28 billion. ResMed had a return on equity of 26.17% and a net margin of 25.34%. The company’s revenue for the quarter was up 7.9% compared to the same quarter last year. During the same period in the previous year, the business earned $2.13 earnings per share.

Hedge Funds Weigh In On ResMed

Institutional investors have recently added to or reduced their stakes in the business. Global X Japan Co. Ltd. increased its stake in ResMed by 121.4% in the first quarter. Global X Japan Co. Ltd. now owns 124 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 68 shares during the last quarter. Colonial Trust Co SC grew its position in ResMed by 6,250.0% during the fourth quarter. Colonial Trust Co SC now owns 127 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 125 shares during the period. Optiver Holding B.V. purchased a new stake in ResMed during the fourth quarter valued at about $33,000. Golden State Wealth Management LLC grew its position in ResMed by 384.8% during the first quarter. Golden State Wealth Management LLC now owns 160 shares of the medical equipment provider’s stock valued at $36,000 after acquiring an additional 127 shares during the period. Finally, Itau Unibanco Holding S.A. grew its position in ResMed by 1,000.0% during the fourth quarter. Itau Unibanco Holding S.A. now owns 165 shares of the medical equipment provider’s stock valued at $38,000 after acquiring an additional 150 shares during the period. 54.98% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at ResMed

In related news, Director Witte Jan De sold 2,000 shares of the company’s stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $243.47, for a total value of $486,940.00. Following the completion of the transaction, the director now directly owns 5,806 shares in the company, valued at approximately $1,413,586.82. This represents a 25.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Kaushik Ghoshal sold 9,745 shares of the company’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $239.31, for a total value of $2,332,075.95. Following the completion of the transaction, the insider now owns 9,725 shares of the company’s stock, valued at $2,327,289.75. The trade was a 50.05% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 50,949 shares of company stock valued at $11,822,260 over the last three months. 0.71% of the stock is currently owned by insiders.

ResMed Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 12th. Stockholders of record on Thursday, May 8th will be issued a $0.53 dividend. The ex-dividend date of this dividend is Thursday, May 8th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 0.87%. ResMed’s dividend payout ratio (DPR) is 23.79%.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.